scispace - formally typeset
Open AccessJournal Article

Marine natural products as anticancer drugs

TLDR
This review highlights several marine natural products and their synthetic derivatives that are currently undergoing clinical evaluation as anticancer drugs.
Abstract
The chemical and biological diversity of the marine environment is immeasurable and therefore is an extraordinary resource for the discovery of new anticancer drugs. Recent technological and methodologic advances in structure elucidation, organic synthesis, and biological assay have resulted in the isolation and clinical evaluation of various novel anticancer agents. These compounds range in structural class from simple linear peptides, such as dolastatin 10, to complex macrocyclic polyethers, such as halichondrin B; equally as diverse are the molecular modes of action by which these molecules impart their biological activity. This review highlights several marine natural products and their synthetic derivatives that are currently undergoing clinical evaluation as anticancer drugs.

read more

Citations
More filters
Journal ArticleDOI

Halogenated Compounds from Corals: Chemical Diversity and Biological Activities

TL;DR: Through large numbers of literature survey, this paper summarized a total of 145 halogenated secondary metabolites which were roughly divided into four major classes of terpenes, prostaglandins, steroids and alkaloids.
Journal ArticleDOI

Antioxidant, antimicrobial and antiproliferative activities of fungal metabolite produced by Aspergillus flavus on in vitro study

TL;DR: In this article , a fungal metabolite was detected by thin layer chromatography and one fungal isolate out of ten isolates bioassayed, was showed to have the most potent antioxidant, antiproliferative and antimicrobial activity; this fungal extract was identified as belonging to Aspergillus flavus (A. flavus).
References
More filters
Journal ArticleDOI

Natural Products as Sources of New Drugs over the Period 1981−2002

TL;DR: From the data presented, the utility of natural products as sources of novel structures, but not necessarily the final drug entity, is still alive and well, and in the area of cancer, the percentage of small molecule, new chemical entities that are nonsynthetic has remained at 62% averaged over the whole time frame.
Journal ArticleDOI

Marine Natural Products and Related Compounds in Clinical and Advanced Preclinical Trials

TL;DR: There are now significant numbers of very interesting molecules that have come from marine sources, or have been synthesized as a result of knowledge gained from a prototypical compound, that are either in or approaching Phase II/III clinical trials in cancer, analgesia, allergy, and cognitive diseases.
Journal ArticleDOI

Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle.

TL;DR: This review describes the biochemistry of tubulin, microtubules, and the mitotic spindle and describes the natural and synthetic agents which are known to interact with tubulin.
Related Papers (5)